Literature DB >> 16409604

Dismembered pyeloplasty in children: a review of 5 years single center experience.

Raanan Tal1, Zvi Bar-Sever, Pinhas M Livne.   

Abstract

AIM: Dismembered pyeloplasty is the treatment of choice for significant ureteropelvic junction obstruction in children. In the present study, we review our experience in 103 pediatric patients and present the clinical characteristics, the surgical treatment and its complications and the long term results.
METHODS: We have reviewed the medical charts of 103 consecutive patients who underwent dismembered pyeloplasty in a 5-year period, from 1997 to 2002. Preoperative data, short- and long-term complications and outcome were recorded. Imaging studies included urinary tract sonography and dynamic renal scans, the results of which were compared pre- and postoperatively.
RESULTS: Most of our patients were boys (81%), diagnosed prenatally (78%). We had no major complications and acceptable incidence of minor complications. Postoperative outcome was excellent, with decreased hydronephrosis (81%), improved renal drainage (87%) and preserved or improved renal function (89%).
CONCLUSION: Dismembered pyeloplasty can be performed with a low incidence of minor complications, no major complications and excellent long-term outcome.

Entities:  

Mesh:

Year:  2005        PMID: 16409604     DOI: 10.1111/j.1442-2042.2005.01201.x

Source DB:  PubMed          Journal:  Int J Urol        ISSN: 0919-8172            Impact factor:   3.369


  2 in total

1.  Postoperative outcome following pyeloplasty in children using miniflank incision and transanastomotic stent: a prospective observational study.

Authors:  Devendra K Gupta; Shilpa Sharma
Journal:  Pediatr Surg Int       Date:  2011-05       Impact factor: 1.827

2.  Therapeutic approaches and long-term follow-up for prenatal hydronephrosis.

Authors:  Bahattin Aydogdu; Gulay Tireli; Oyhan Demirali; Unal Guvenc; Cemile Besik; Serdar Sander; Aysel Kiyak
Journal:  Pak J Med Sci       Date:  2016 May-Jun       Impact factor: 1.088

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.